How does Feihe International Inc. turn premium infant formula and lifecycle nutrition into repeat revenue in China?
Feihe International Inc. sells premium infant and adult nutrition through a vertically integrated supply chain, branded portfolio, and direct retail channels. In 2025 it reports sustained gross margins and expanding e-commerce mix, signaling resilience despite falling birth rates. Feihe SWOT Analysis

Feihe monetizes trust: repeat purchases, subscription bundles, and cross-sell to older demographics drive unit economics and lifetime value. Watch inventory turns and online repeat-rate for durability insights.
What Does Feihe Actually Sell?
Feihe International Inc. sells premium infant formula and expanding nutrition products, emphasizing formulas tailored to Chinese infants, plus adult milks and liquid dairy; customers buy specialized nutrition, safety, and localized science for health and development.
Feihe infant formula portfolio centers on flagship lines such as Astrobaby and Organic Zhenzhi, using ingredients like OPO fats, lactoferrin, and Human Milk Oligosaccharides (HMOs). Beyond powder formula, Feihe sells adult milk powders for the Silver Economy, functional supplements, and liquid milk products through retail and e-commerce.
Core customers are Chinese parents of infants and caregivers for older adults; distribution focuses on Chinese supermarkets, pharmacy chains, cross-border and domestic e-commerce, and institutional sales to hospitals and maternal-child stores.
Customers receive nutrition positioned as physiologically matched to Chinese infants, backed by targeted ingredients and in-house R&D; for elders, products promise protein, calcium, and functional benefits supporting mobility and immunity. Trust and perceived safety command premium pricing.
Feihe company differentiates via localized formulation, vertically integrated Feihe manufacturing and supply chain control, and traceability to partnered dairy farms. Brand trust, clinical-style ingredient claims, and wide e-commerce reach make switching costs higher for parents seeking premium Feihe infant formula; see the company history for context: History of Feihe Company Explained
Feihe SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does Feihe Run Day to Day?
Feihe International Inc. runs day-to-day on a vertically integrated cow-to-cup model that controls raw milk sourcing, processing, and sales to preserve bioactivity and ensure traceability. Operational focus is on rapid conversion-raw milk to formula within 24 hours-AI-driven Smart Factories, and an omnichannel distribution network that reaches consumers directly.
Feihe company integrates forage, dairy farms in Heilongjiang's Golden Milk Belt, processing plants, and sales so operations minimize third-party dependence and control quality.
Feihe infant formula reaches mothers via over 100,000 retail points plus direct digital sales on Feihe Star Ma and e-commerce, enabling direct-to-consumer fulfilment and faster feedback loops.
Daily operations follow the Two-Hour Fresh Milk Circle: milk harvested from owned/partner farms is transported to plants, with conversion into formula within 24 hours to retain bioactivity and meet product specs.
Sales run through physical retail, Feihe Star Ma digital ecosystem, and major e-commerce platforms; logistics coordinate temperature-controlled flows to preserve product integrity from plant to store or home.
Smart Factories use AI for real-time testing and blockchain for end-to-end traceability; partnerships with regional dairy farms and investments in self-owned ranches secure raw milk volume and quality.
The combination of the Two-Hour Fresh Milk Circle, AI-driven quality checks, and blockchain traceability reduces spoilage, shortens lead times, and supports premium pricing and consumer trust.
Feihe business model runs as a tightly sequenced supply chain: daily milk collection from Heilongjiang farms, rapid transport into Smart Factories for AI-monitored processing, blockchain logging for traceability, then distribution through retail and digital channels to mothers nationwide.
- The core operating model is vertical integration from forage and farms to formula production and sales.
- Products are delivered via over 100,000 retail touchpoints plus Feihe Star Ma and e-commerce for direct consumer sales.
- Main supporting systems include Smart Factories with AI testing, blockchain traceability, and farm partnerships in the Golden Milk Belt.
- The model works efficiently because milk-to-formula turnaround is under 24 hours, preserving bioactivity and enabling premium positioning.
For competitive context and market positioning, see Who Feihe Company Competes With
Feihe PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Money Come In at Feihe?
Feihe Company earns most revenue by selling tiered nutritional products, led by super-premium infant formula which captures the largest margins; in 2025 the group reported annual revenue of 18.11 billion yuan with super – premium SKUs making up about 76 percent of sales. The monetization shift in 2025 emphasized value extraction per customer and growing non – infant lines now at roughly 12 percent of group revenue.
Feihe infant formula is the primary revenue engine, selling high – margin SKUs with institutional – grade gross margins above 65 percent on premium infant lines, well above the industry average of 45-50 percent; this pricing power preserves profitability despite volume declines.
Feihe operations expanded non – infant offerings-adult nutrition and other dairy-contributing approximately 12 percent of 2025 group revenue, diversifying mix and reducing dependence on infant formula volumes.
Feihe business model relies on one – time product sales with tiered pricing: super – premium SKUs command high unit prices; occasional bundles and multipack promotions support retention but revenue comes mainly from high – ASP product sales.
Revenue depends on product mix and pricing power-super – premium share, repeat purchase rates for infant formula, and channel distribution (offline retail plus growing e – commerce sales) determine top – line performance.
Feihe converts demand into revenue by selling high – ASP, super – premium infant formula that drives margins and using product mix shifts (adult nutrition growth) to stabilize sales; in 2025, revenue fell 12.7 percent year – over – year to 18.11 billion yuan as industry adjustments compressed volumes but not gross margins.
- Primary: super – premium Feihe infant formula with >65 percent gross margins
- Secondary: adult nutrition and other dairy products (~12 percent of revenue)
- Model: one – time tiered sales, high ASP, bundles and channel promotions
- Strongest driver: product mix and pricing power-super – premium lines ~76 percent of 2025 revenue
For deeper strategic context and forward – looking positioning, see Where Feihe Company Is Going
Feihe SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Makes Feihe's Model Strong or Fragile?
Feihe International Inc. has strong brand equity and vertical integration, but heavy dependence on China's infant formula market makes the model fragile. Strengths: 70 percent brand awareness and in-house supply reduce margin pressure; Vulnerabilities: 2025 births fell to 7.92 million, cutting net profit about 45.7% to 1.939 billion yuan.
Feihe company benefits from massive brand recognition in China and a vertically integrated manufacturing footprint, which supports pricing power and rapid response during supply shocks.
Assets include proprietary Feihe manufacturing plants, tight Feihe supply chain traceability and sourcing relationships with dairy farms, and quality control labs that underpin Feihe infant formula safety standards and support R&D for product line extension.
Revenue concentraton in infant formula exposes Feihe operations to demographic risk: China's 2025 births dropped to 7.92 million (down 17% YoY), pressuring volumes and channel mix despite online and offline Feihe distribution channels in China.
The model is resilient short-term due to brand and manufacturing control, but structurally fragile long-term: 2025 net profit fell to 1.939 billion yuan (-45.7% YoY), making growth hinge on Feihe international expansion and successful pivot to adult and full-lifecycle nutrition.
Feihe business model works because vertical integration and brand equity buffer price wars, but demographic collapse and concentration in infant formula make future valuation a bet on diversification speed and overseas traction.
- High structural strength: 70 percent brand awareness among Chinese parents
- Most important capability: in-house Feihe manufacturing, supply chain traceability and quality-control labs
- Key constraint: reliance on China infant formula market after 2025 births fell to 7.92 million
- Resilience view: exposed long-term unless pivot to adult nutrition and exports scales quickly
For operational detail on channels and go-to-market moves, see How Feihe Company Sells
Feihe VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Feihe sells premium infant formula and expanding nutrition products. Its lineup includes flagship infant formulas like Astrobaby and Organic Zhenzhi, plus adult milk powders, functional supplements, and liquid dairy products. The blog says buyers are mainly looking for specialized nutrition, safety, and localized science.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.